How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 8, 2015, Pages 862-865

  Kucur, Suna Kabil ^a   Gozukara, Ilay ^a   Aksoy, Aysenur ^b   Uludag, Eda U ^b   Keskin, Havva ^c   Kamalak, Zeynep ^b   Carlioglu, Ayse ^c  

^a DUMLUPINAR UNIVERSITY   (Turkey)

^b Nenehatun Obstetrics and Gynecology Hospital   (Turkey)

^c Bolge Training and Research Hospital ^*  (Turkey)

Author keywords

Cardiovascular risk; Mean platelet volume; Polycystic ovary syndrome; White blood cell count

Indexed keywords

C REACTIVE PROTEIN; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; INSULIN; METFORMIN; PRASTERONE SULFATE; TESTOSTERONE; ANTIANDROGEN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CYPROTERONE ACETATE; CYPROTERONE ACETATE, ETHINYL ESTRADIOL DRUG COMBINATION; DRUG COMBINATION; ETHINYLESTRADIOL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FERRIMAN GALLWEY SCORE; HEMATOLOGICAL PARAMETERS; HOMEOSTASIS; HOMEOSTATIC MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; THROMBOCYTE VOLUME; TREATMENT DURATION; YOUNG ADULT; ADOLESCENT; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPLICATION; DRUG COMBINATION; METABOLISM; PATHOLOGY; POLYCYSTIC OVARY SYNDROME; REGRESSION ANALYSIS; THROMBOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; BIOMARKERS; BLOOD PLATELETS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CYPROTERONE ACETATE; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LEUKOCYTE COUNT; MEAN PLATELET VOLUME; METFORMIN; POLYCYSTIC OVARY SYNDROME; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84947126448     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000229     Document Type: Article

References (26)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745-2749.
2. Fauser BCJM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome: Rotterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2004; 81:19-25.
3. Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone B, et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 2008; 23:153-159.
4. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011; 17:741-760.
5. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83:1454-1460.
6. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:1741-1747.
7. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:1357-1363.
8. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insülin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38:1165-1174.
9. Kebapcilar L, Taner CE, Kebapcilar AG, Sari I. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 2009; 280:187-193.
10. Caglar GS, Oztas E, Karadag D, Pabuccu R, Eren AA. The association of urinary albumin excretion and metabolic complications in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011; 154:57-61.
11. Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002; 13:301-306.
12. Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke 2004; 35:1688-1691.
13. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular disease. Int J Clin Pract 2009; 63:1509-1515.
14. Gursoy A, Ertugrul DT, Pamuk B, Sahin M, Asik M, Yilmaz H, et al. Mean platelet volume in patients with polycystic ovary disease. Platelets 2006; 17:505-506.
15. Kebapcilar L, Taner CE, Kebapcilar AG, Alacacioglu A, Sari I. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Arch Gynecol Obstet 2010; 281:35-42.
16. Harborne L, Flemming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003; 361:1894-1901.
17. De Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update 2011; 17:495-500.
18. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93:1276-1284.
19. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007; 24:CD005552.
20. Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010; 95:722-730.
21. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:4588-4593.
22. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8:148-156.
23. Petitti DB. Oral contraceptives and hypercoagulation. Clin Adv Hematol Oncol 2006; 4:813-815.
24. Seaman HE, de Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod 2003; 18:522-526.
25. Luque-Ramírez M, Mendieta-Azcona C, del Rey Sánchez JM, Matíes M, Escobar-Morreale HF. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. Eur J Endocrinol 2009; 160:469-480.
26. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanovà L, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:2-5.